$heff's $tation of $tocks & $olid DD

[$heff]

$SNSS..Sunesis Pharmaceuticals Inc.'s vosaroxin is also in a late-stage Phase 3 trial, but as a second-line treatment in combination with cytarabine for relapsed or refractory acute myeloid leukemia. Vosaroxin is an antineoplastic quinolone derivative that is not a P-glycoprotein (P-gp) substrate, and may avoid the P-gp-mediated drug resistance seen in anthracyclines. The company expects to announce the Phase 3 data later this year in late Q3/early Q4.